A 42-year-old woman with MEN-1 syndrome is found to have a prolactin-secreting pituitary adenoma (prolactinoma) on screening MRI. She presents with amenorrhea and galactorrhea. Dopamine agonist therapy is indicated. Which agent is the preferred first-line drug of choice for prolactinoma in MEN-1?

Explanation

## Pharmacological Management of Prolactinoma in MEN-1 ### First-Line Dopamine Agonist **Key Point:** Cabergoline is the preferred first-line dopamine agonist for prolactinoma in MEN-1 syndrome due to superior efficacy, tolerability, and lower rates of side effects compared to bromocriptine. **High-Yield:** Cabergoline has a longer half-life (65 hours), higher selectivity for D₂ receptors, and better tissue penetration than bromocriptine. It normalizes prolactin levels in >90% of patients and allows tumor shrinkage in most cases. ### Comparative Pharmacology of Dopamine Agonists | Feature | Cabergoline | Bromocriptine | Quinagolide | |---------|-------------|---------------|-------------| | **Half-life** | 65 hours | 3–8 hours | 17–19 hours | | **Dosing frequency** | 2× weekly | 2–3× daily | 1× daily | | **D₂ selectivity** | Very high | Moderate | High | | **Prolactin normalization** | >90% | ~80% | ~85% | | **Tumor shrinkage** | 60–70% | 40–50% | ~60% | | **Side effect profile** | Excellent | Nausea, orthostasis, headache | Moderate | | **Cardiac valvulopathy risk** | Minimal (>2 years) | Minimal | Minimal | ### Mechanism of Action - Dopamine agonists bind D₂ receptors on lactotroph cells - Suppress prolactin secretion and induce apoptosis - Lead to tumor shrinkage and restoration of gonadal function ### Clinical Advantages of Cabergoline in MEN-1 **Clinical Pearl:** Cabergoline's longer half-life and twice-weekly dosing improve compliance, particularly important in MEN-1 patients who require long-term management of multiple endocrine tumors. The lower incidence of nausea and gastrointestinal side effects also enhances tolerability. ### Monitoring During Therapy 1. Serum prolactin levels (target: <20 ng/mL) 2. Pituitary MRI at 6–12 months to assess tumor response 3. Echocardiography if long-term use (>2 years) is planned, though cardiac valve abnormalities are rare with cabergoline 4. Visual fields if macroadenoma with suprasellar extension **Warning:** Metoclopramide is a dopamine antagonist and will worsen prolactin secretion—it is contraindicated in prolactinoma. [cite:Harrison 21e Ch 375]